Empower your strategies with our Net Present Value Model: Pfizer Inc’s PF-06425090 report and make more profitable business decisions.
Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development.
Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.

Pfizer Inc’s PF-06425090 Drug Details:
PF-06425090 vaccine is under development for the prevention of Clostridium difficile infections. The vaccine is administered via intramuscular route as powder for suspension. The vaccine candidate is genetically modified toxins in a non-sporulating strain of C. difficile that lacks the toxin genes tcdA and tcdB.It was also under development for infectious diarrhea and pseudomembranous colitis.
Report Coverage
GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.
Scope of Report
- Drug Name
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
- Patent law
- Known and Projected regulatory approval processes
- Cash flows
- Potential applicable patients
- Drug margins
- Company expenses
- Pricing estimates
Reasons to buy
- Obtain a better understanding of the quantitative value of Net Present Value Model: Pfizer Inc’s PF-06425090.
- Access another data source to use in the valuation of Net Present Value Model: Pfizer Inc’s PF-06425090.
- Create or support internal NPV models to improve accuracy.
- Understand a drug’s expected profit, considering revenue and cost forecasts leveraging public and proprietary data sets.







